Dr. Teaniese \u201cTina\u201d Davis is a Research Investigator II at the Center for Research and Evaluation. She is a behavioral scientist with a focus on intervention development and evaluation and serves as a team lead for the Research Investigator team.<\/p>\n
Dr. Davis attended Spelman College and completed her doctoral training in health promotion and behavior at the University of Georgia. She has extensive experience adapting evidence-based health interventions for specific populations using mixed-methods research. Dr. Davis is a member of the Social Needs Network for Evaluation and Translation (SONNET) Evaluation and Research Committee and serves on the Health Care Systems Research Network (HCSRN) Executive Committee.<\/p>\n
Publications:<\/strong> NCBI Collections<\/a>[\/vc_column_text][divider line_type=”Full Width Line” line_thickness=”1″ divider_color=”extra-color-gradient-2″ custom_height=”40″ custom_height_tablet=”20″ custom_height_phone=”10″][vc_column_text css=”.vc_custom_1771016088445{margin-bottom: 0px !important;padding-bottom: 0px !important;}” text_direction=”default”]\n The goal of this research is to test the feasibility of a culturally adapted and tailored intervention (T1DES) to enhance diabetes management strategies among Black young adults with Type 1 Diabetes, addressing the pervasive racial disparity in health outcomes.<\/p>\n Funders:<\/strong> National Institute of Diabetes and Digestive and Kidney Disease<\/a> and The Leona M. and Harry B Helmsley Charitable Trust<\/a> <\/p>\n The goals of this study are to evaluate the use and outcomes of long-acting injectable pre-exposure prophylaxis (LAI PrEP) to prevent HIV in high-priority populations (e.g., Black women, Black and Latino MSM), quantify the long-term impact on HIV and equity outcomes, and optimize investment of resources in interventions to support LAI PrEP use in three racially and ethnically diverse regions of Kaiser Permanente\u2014Northern California, Mid-Atlantic, and Georgia. These regions collectively serve 5.6 million members and 13,000 PrEP users.<\/p>\n Funder:<\/strong> National Institute of Allergy and Infectious Diseases<\/a> <\/p>\n This study will implement an enhanced recovery protocol for children undergoing gastrointestinal surgery in 18 US hospitals to evaluate whether it improves clinical outcomes.<\/p>\nSelected Research:<\/h4>\n
Effectiveness pilot of the Type 1 Diabetes Education and Support (T1DES) intervention among black young adults at an integrated network and a public hospital<\/strong><\/h5>\n
\nEnd Date:<\/strong> 3\/30\/2025<\/p>\nCabotegravir PrEP: Actionable Robust Evidence for Translation into Practice (CABARET)<\/strong><\/h5>\n
\nEnd Date<\/strong>: 7\/31\/2027<\/p>\nENhanced Recovery In CHildren Undergoing Surgery for inflammatory bowel disease study (<\/strong>ENRICH-US<\/strong><\/a>)<\/strong><\/h5>\n